BDX · News · 20260809N
Licensing / Collaboration Deals
BECTON DICKINSON & CO · 2026-08-09 · Importance 31 · Surprise 42 · In source text
Becton Dickinson highlighted new biologic drug-delivery partnerships tied to GLP-1 medicines. The collaborations include a semaglutide pen partnership in Brazil using the company’s Vystra Injection Pen platform. The reported initiative expands BD’s drug-delivery opportunity in Brazil and targets continued growth in biologic and GLP-1 administration.
Key facts
- Becton Dickinson announced a semaglutide pen collaboration in Brazil leveraging its Vystra Injection Pen platform. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Becton Dickinson announced a semaglutide pen collaboration in Brazil leveraging its Vystra Injection Pen platform. |